Literature DB >> 11001756

Nitric oxide may be required to prevent hypertension at the onset of diabetes.

S M Fitzgerald1, M W Brands.   

Abstract

Nitric oxide (NO) plays an important role in the regulation of vascular tone, and evidence suggests that endothelial-dependent relaxation, possibly mediated via NO, is impaired in diabetes. However, the role of the endothelium in arterial pressure control early in diabetes, before dysfunction develops, is not known. This was evaluated in the present study by comparing the responses to induction of diabetes in vehicle-treated rats (D, n = 7) vs. rats chronically treated with N(G)-nitro-L-arginine methyl ester (L-NAME; D+L, n = 8). A nondiabetic group also was treated with L-NAME (L, n = 7) to control for L-NAME effects over time, independent of diabetes. After baseline measurements, rats were given either vehicle or L-NAME (10 microg. kg(-1). min(-1) iv) infusion throughout the experiment. Six days later, streptozotocin (60 mg/kg iv) was administered, followed by a 3-wk diabetic study period. Induction of diabetes in the D+L rats caused a marked and progressive increase in mean arterial pressure throughout the diabetic period, averaging approximately 70 mmHg greater than in the D rats and approximately 20 mmHg greater than in the L rats. Glomerular filtration rate and renal plasma flow tended to increase during diabetes, but this trend was reversed in the D+L rats. In addition, plasma renin activity increased in the D and D+L rats during week 1 of diabetes but then returned to control in the D rats, while continuing to increase in the D+L rats. These results suggest that, in the early stages of diabetes, NO synthesis is important to prevent hypertension from developing, possibly through actions to maintain glomerular filtration and suppress renin secretion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001756     DOI: 10.1152/ajpendo.2000.279.4.E762

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  8 in total

Review 1.  Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.

Authors:  Peter N Van Buren; Robert Toto
Journal:  Adv Chronic Kidney Dis       Date:  2011-01       Impact factor: 3.620

2.  Na+,K+-ATPase is modulated by angiotensin II in diabetic rat kidney--another reason for diabetic nephropathy?

Authors:  Andrea Fekete; Klara Rosta; Laszlo Wagner; Agnes Prokai; Peter Degrell; Eva Ruzicska; Edit Vegh; Miklos Toth; Katalin Ronai; Krisztina Rusai; Aniko Somogyi; Tivadar Tulassay; Attila J Szabo; Agota Ver
Journal:  J Physiol       Date:  2008-09-25       Impact factor: 5.182

Review 3.  Role of glomerular filtration rate in controlling blood pressure early in diabetes.

Authors:  Michael W Brands; Hicham Labazi
Journal:  Hypertension       Date:  2008-07-07       Impact factor: 10.190

Review 4.  Regulation of carbohydrate metabolism by nitric oxide and hydrogen sulfide: Implications in diabetes.

Authors:  Sevda Gheibi; Alan P Samsonov; Shahsanam Gheibi; Alexandra B Vazquez; Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2020-01-21       Impact factor: 5.858

5.  Continuously measured renal blood flow does not increase in diabetes if nitric oxide synthesis is blocked.

Authors:  Tracy D Bell; Gerald F DiBona; Rachel Biemiller; Michael W Brands
Journal:  Am J Physiol Renal Physiol       Date:  2008-08-27

Review 6.  Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins.

Authors:  Thomas D Giles; Gary E Sander; Bobby D Nossaman; Philip J Kadowitz
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-04       Impact factor: 3.738

7.  Endothelial dysfunction in diabetes: potential application of circulating markers as advanced diagnostic and prognostic tools.

Authors:  Worku Abebe; Mahmood Mozaffari
Journal:  EPMA J       Date:  2010-03-10       Impact factor: 6.543

8.  Nitric oxide bioavailability and its potential relevance to the variation in susceptibility to the renal and vascular complications in patients with type 2 diabetes.

Authors:  Kenneth A Earle; Diane Harry; Mitra Madhavi; Karima Zitouni; Jeffrey Barron
Journal:  Diabetes Care       Date:  2008-10-22       Impact factor: 19.112

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.